| Code | CSB-RA001950MB12HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Remternetug, targeting amyloid precursor protein (APP). APP is a transmembrane protein that plays crucial roles in neuronal development, synaptic plasticity, and cell adhesion. Proteolytic processing of APP by β-secretase and γ-secretase generates amyloid-beta (Aβ) peptides, which aggregate to form the characteristic amyloid plaques found in Alzheimer's disease. Dysregulation of APP processing and accumulation of Aβ oligomers and fibrils are central pathological features associated with neurodegeneration and cognitive decline in Alzheimer's disease and related dementias.
Remternetug is a humanized IgG1 monoclonal antibody that selectively binds to specific APP epitopes, designed to modulate amyloid pathology. This biosimilar provides researchers with a valuable tool for investigating APP biology, amyloid cascade mechanisms, and potential therapeutic interventions in neurodegenerative disease models. It supports studies examining APP processing pathways, protein-protein interactions, and the role of amyloid species in neuronal dysfunction, making it suitable for Alzheimer's disease research and related neuroscience applications.
There are currently no reviews for this product.